Setting up a showdown with Boehringer, Pfizer scores interchangeability tag for its Humira biosimilar

Beginning later this month, Pfizer is launching an interchangeable biosimilar to AbbVie’s blockbuster rheumatoid arthritis drug Humira (adalimumab) at a 5% discount on the wholesale acquisition price.

Later in 2023, Pfizer said late last week, its interchangeable biosimilar known as Abrilada (adalimumab-afzb) will be available at a second list price…
Click here to view original post